jens juul holst glp 1 GLP-1s, should we all be taking them?' GLP-1 weight loss discoverers win

As of mid-2026, Retatrutide is still in Phase 3 trials, with FDA approval expected late this year or early next

It's worth noting that GLP-1 receptor agonists should be used with caution in people with severe gastrointestinal disease, including severe gastroparesis, as these conditions may be exacerbated by further slowing of gastric emptying

Finally, because estrogen helps maintain insulin sensitivity, decreased levels are linked to poor glucose uptake and unhealthy changes in cholesterol

Managing stress supports your overall weight loss efforts

10.1179/147683010X12611460763922 10

The injection technique is identical for both, and the same injection sites work for either compound